Genetics

The pharmaceutical industry has always been notoriously risky. As one of the most capital-intensive businesses in the world, it requires massive investment in order to obtain FDA approval of drugs. However, this process is fraught with peril, oftentimes resulting in drug after drug failing to achieve final FDA approval. Ultimately, these costs are borne by …

Continue reading Under Clay Siegall’s leadership, Seattle Genetics pursues diverse revenue sources